Doximity, Inc.
DOCSDoximity, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved −11.7% against a −64.4% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (31 weeks in). Underneath, the last four quarters read deteriorating — profit −66.7% year on year, and 137% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Doximity, Inc. trades at $25.9, in a downtrend and 31 weeks into that stage. That is −7.5% against its own 200-day average. It sits at 13% of a 52-week range of $19 to $74. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 7 straight weeks.
Today the stock is in a downtrend — week 31 of stage 4. At $25.9 it trades −7.5% versus its 200-day average and sits at 13% of its 52-week range ($19–$74).
Against the market, two honest reads. Cumulative: over the last 5.2 years the stock moved −54% while the S&P 500 moved +77% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Doximity, Inc. trades at 30.8× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.8× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −11.7% against a −64.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +6.9%/yr price move, ~+21.6%/yr came from earnings growth and ~−14.7 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Doximity, Inc. reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +46.7% at its peak → −13.6% latest) while ROCE still reads 19.3%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +12.3% | +15.1% | — | — |
| Profit | −9.1% | +22.1% | — | — |
| EPS | −11.7% | +22.7% | — | — |
| Stock price | −64.4% | +6.9% | −23.0% | — |
4-Factor Sector Score
43.2/100 — rank 20 of 29 in Health Information Services · 81% evidence confidence
Doximity, Inc. scores 43.2 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 20. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.1 + 15.9 + 10.9 + 5.3 = 43.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Doximity, Inc. reported $0.1 B of revenue in the Mar 26 quarter, +7.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 17.1% a year. The last full year, FY26, came in at $0.6 B. The last four reported quarters add to $0.7 B.
FY26 revenue came in at $0.6 B (+12.3% on the year), capping 4 years at 17.1% compound. The latest quarter (Mar 26) printed $0.1 B, +7.1% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +13.9% growth against the decade's 17.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +13.8% over the last 4 quarters against +17.3%/yr over the last 8 — rolling over; TTM profit −13.6% vs +12.5%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Doximity, Inc.'s operating margin is 13.3% in the Mar 26 quarter, −22.4 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 31.0% to 40.4%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 13.3%, −22.4 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 31.0%–40.4%.
🚨 Why the margin moved: operating margin went −22.4 pp year on year while gross margin went +1.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Doximity, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −66.7% year on year. Full-year FY26 profit was $0.2 B. The 4-year compound rate is 7.5%. That is 13.3% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.0 B, −66.7% year on year. On the full year, FY26 printed $0.2 B (−9.1%), and the 4-year compound rate is 7.5%.
🚨 Why profit moved: revenue contributed +7.1% and the margin −22.4 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −4.2% vs revenue +13.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 137% of Doximity, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $0.3 B of operating cash against $0.2 B of profit. After null of capital spending, $0.3 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of $0.3 B against reported profit of $0.2 B, leaving free cash of $0.3 B after null of capital spending. Across the last 3 fiscal years the conversion rate is 137% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Doximity, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Doximity, Inc. earns a ROE of 21% in FY26. That is up from a trough of 11% in FY23. Return on invested capital clears the cost of that capital by +54.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 31.3% net margin on 0.57× asset turns.
FY26 ROE is 21%, recovered from a FY23 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 31.3% net margin × 0.57× asset turns × 1.18× balance-sheet leverage ≈ 21.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 65.7% − 11.1% = a +54.6 pp spread. The 11.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Doximity, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Doximity, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Doximity, Inc. carries total debt of $0.0 B against shareholder equity of $0.9 B as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $0.9 B — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
11.4% of Doximity, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 1.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 11.4% of the float is sold short, and at typical trading volumes it would take about 1.9 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Doximity, Inc.: the Z-score reads 31.30. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 31.30 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 31.30.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Veeva Systems Inc.VEEV | 64.7/100Mixed-positive evidence85% evidence | BREAKING OUT | 19.8/35 Revenue 16.3% · PAT 20.5% · OPM change 0.1 pp 95% evidence | 17.7/25 ROCE 4% · OPM 30.9% 76% evidence | 13.1/20 P/E 27.8× · PEG 1.47 65% evidence | 14.1/20 RS sector -3.9% · RS bench 14.8% · 1Y -4.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 17.7 + 13.1 + 14.1 = 64.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Hinge Health, Inc.HNGE | 60.0/100Mixed-positive evidence68% evidence | LEADER | 19.7/35 Revenue 49.5% · PAT -1748.4% · OPM change 7 pp 83% evidence | 15.0/25 ROCE 8.4% · OPM 17.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.3/20 RS sector 31.5% · RS bench 56.4% · 1Y 64.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 15 + 10 + 15.3 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Simulations Plus, Inc.SLP | 59.5/100Thin evidence · provisional52% evidence | FADING | 24.4/35 Revenue — · PAT — · OPM change 11.1 pp 45% evidence | 16.2/25 ROCE 3.4% · OPM 23.2% 76% evidence | 10.2/20 P/E 42.8× · PEG — 15% evidence | 8.7/20 RS sector -12.5% · RS bench 5.1% · 1Y 20.9%11 of 12 weeks ahead 70% evidence |
| Exact sum: 24.4 + 16.2 + 10.2 + 8.7 = 59.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Waystar Holding Corp.WAY | 57.5/100Mixed-positive evidence85% evidence | BREAKING OUT | 21.3/35 Revenue 19.4% · PAT 58.8% · OPM change -0.2 pp 95% evidence | 12.7/25 ROCE 1.5% · OPM 23.8% 76% evidence | 15.9/20 P/E 29.3× · PEG 0.64 65% evidence | 7.6/20 RS sector -24.2% · RS bench -8.9% · 1Y -29.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 12.7 + 15.9 + 7.6 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 510x Genomics, Inc.TXG | 56.8/100Mixed-positive evidence61% evidence | LEADER | 20.2/35 Revenue 2.2% · PAT — · OPM change 14.1 pp 62% evidence | 6.9/25 ROCE -2% · OPM -11.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.7/20 RS sector 109.2% · RS bench 147.4% · 1Y 457.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 6.9 + 10 + 19.7 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6HealthEquity, Inc.HQY | 55.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 23.2/35 Revenue 7.6% · PAT 89.3% · OPM change 3.9 pp 95% evidence | 15.5/25 ROCE 3.2% · OPM 29% 76% evidence | 11.8/20 P/E 30.7× · PEG 1.57 65% evidence | 5.3/20 RS sector -17.6% · RS bench -0.5% · 1Y 2.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 15.5 + 11.8 + 5.3 = 55.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -17.6% and the one-year return is 2.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7BrightSpring Health Services, Inc.BTSG | 51.3/100Thin evidence · provisional58% evidence | ASLEEP | 19.5/35 Revenue — · PAT — · OPM change 1.6 pp 45% evidence | 12.7/25 ROCE 2.9% · OPM 3.4% 76% evidence | 10.0/20 P/E 44.4× · PEG — 15% evidence | 9.1/20 RS sector -3.1% · RS bench 17.5% · 1Y 115.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 12.7 + 10 + 9.1 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Omada Health, Inc.OMDA | 50.1/100Thin evidence · provisional55% evidence | BREAKING OUT | 25.1/35 Revenue 49% · PAT — · OPM change 9.2 pp 62% evidence | 7.0/25 ROCE -2.9% · OPM -6.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.0/20 RS sector -13.5% · RS bench 2.9% · 1Y -13%12 of 12 weeks ahead 70% evidence |
| Exact sum: 25.1 + 7 + 10 + 8 = 50.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9HeartFlow, Inc.HTFL | 49.7/100Thin evidence · provisional55% evidence | BREAKING OUT | 19.9/35 Revenue 40.4% · PAT — · OPM change -9.1 pp 62% evidence | 3.8/25 ROCE -13.2% · OPM -56.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.0/20 RS sector 20.5% · RS bench 44% · 1Y 46.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 19.9 + 3.8 + 10 + 16 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Phreesia, Inc.PHR | 47.5/100Mixed-negative evidence67% evidence | BREAKING OUT | 22.6/35 Revenue 13.8% · PAT 100% · OPM change 8 pp 71% evidence | 10.9/25 ROCE 1.7% · OPM 5.2% 76% evidence | 9.6/20 P/E 61.4× · PEG — 15% evidence | 4.4/20 RS sector -42.8% · RS bench -31.7% · 1Y -57.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 10.9 + 9.6 + 4.4 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11HealthStream, Inc.HSTM | 46.9/100Mixed-negative evidence81% evidence | BREAKING OUT | 18.4/35 Revenue 6.5% · PAT 5.3% · OPM change 3.3 pp 83% evidence | 14.2/25 ROCE 1.9% · OPM 9.3% 76% evidence | 5.6/20 P/E 30.9× · PEG 4.87 65% evidence | 8.7/20 RS sector -6.6% · RS bench 12.3% · 1Y 1.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 14.2 + 5.6 + 8.7 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Weave Communications, Inc.WEAV | 46.7/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.6/35 Revenue 16.4% · PAT — · OPM change 7.5 pp 62% evidence | 5.7/25 ROCE -5.1% · OPM -9.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.4/20 RS sector -7.7% · RS bench 10.9% · 1Y -3.8%10 of 12 weeks ahead 70% evidence |
| Exact sum: 21.6 + 5.7 + 10 + 9.4 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13SOPHiA GENETICS SASOPH | 46.2/100Thin evidence · provisional55% evidence | BREAKING OUT | 17.1/35 Revenue 19.1% · PAT — · OPM change 10.5 pp 62% evidence | 3.4/25 ROCE -15.1% · OPM -79.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.7/20 RS sector 17.4% · RS bench 41.2% · 1Y 140.1%10 of 12 weeks ahead 70% evidence |
| Exact sum: 17.1 + 3.4 + 10 + 15.7 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Carlsmed, Inc.CARL | 46.1/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.2/35 Revenue 75% · PAT — · OPM change -1.5 pp 62% evidence | 4.0/25 ROCE -11.7% · OPM -57.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.9/20 RS sector -4.1% · RS bench 15.3% · 1Y 8.2%9 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 4 + 10 + 10.9 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Tempus AI, Inc.TEM | 45.0/100Thin evidence · provisional55% evidence | BREAKING OUT | 18.7/35 Revenue — · PAT — · OPM change 2.6 pp 45% evidence | 5.6/25 ROCE -4.8% · OPM -24.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.7/20 RS sector -10.7% · RS bench 6.9% · 1Y -20.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 5.6 + 10 + 10.7 = 45 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Schrödinger, Inc.SDGR | 44.9/100Thin evidence · provisional58% evidence | LEADER | 15.5/35 Revenue 10.9% · PAT — · OPM change 2.2 pp 62% evidence | 4.6/25 ROCE -9.4% · OPM -83.3% 76% evidence | 9.4/20 P/E 66.3× · PEG — 15% evidence | 15.4/20 RS sector 17% · RS bench 39.6% · 1Y 23%12 of 12 weeks ahead 70% evidence |
| Exact sum: 15.5 + 4.6 + 9.4 + 15.4 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Omnicell, Inc.OMCL | 44.7/100Thin evidence · provisional58% evidence | BASING | 21.1/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence | 12.8/25 ROCE 2.1% · OPM 5.4% 76% evidence | 9.8/20 P/E 49.4× · PEG — 15% evidence | 1.0/20 RS sector -36% · RS bench -22% · 1Y 3.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 12.8 + 9.8 + 1 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18NRC HealthNRC | 44.4/100Thin evidence · provisional52% evidence | LEADER | 12.3/35 Revenue — · PAT — · OPM change -9.6 pp 45% evidence | 11.5/25 ROCE -3.1% · OPM 16% 76% evidence | 9.1/20 P/E 86.3× · PEG — 15% evidence | 11.5/20 RS sector -3.8% · RS bench 16.4% · 1Y 49%11 of 12 weeks ahead 70% evidence |
| Exact sum: 12.3 + 11.5 + 9.1 + 11.5 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19TruBridge, Inc.TBRG | 43.8/100Thin evidence · provisional58% evidence | 10.6/35 Revenue 0% · PAT — · OPM change -5.9 pp 62% evidence | 10.0/25 ROCE 0.9% · OPM 3.5% 76% evidence | 9.3/20 P/E 73.2× · PEG — 15% evidence | 13.9/20 RS sector 3.7% · RS bench 11% · 1Y 18.9%2 of 2 weeks ahead to 2026-07-10 70% evidence | |
| Exact sum: 10.6 + 10 + 9.3 + 13.9 = 43.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Doximity, Inc.this pageDOCS | 43.2/100Mixed-negative evidence81% evidence | BREAKING OUT | 11.1/35 Revenue 13% · PAT -11.7% · OPM change -18.1 pp 83% evidence | 15.9/25 ROCE 2.4% · OPM 17.1% 76% evidence | 10.9/20 P/E 23.8× · PEG 1.84 65% evidence | 5.3/20 RS sector -41.2% · RS bench -30.1% · 1Y -64.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.1 + 15.9 + 10.9 + 5.3 = 43.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Privia Health Group, Inc.PRVA | 39.9/100Mixed-negative evidence81% evidence | ASLEEP | 22.2/35 Revenue 24.7% · PAT 40% · OPM change 0.1 pp 83% evidence | 11.1/25 ROCE 1% · OPM 1.2% 76% evidence | 4.5/20 P/E 128.6× · PEG 3.86 65% evidence | 2.1/20 RS sector -32.7% · RS bench -18.4% · 1Y -8.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 11.1 + 4.5 + 2.1 = 39.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22GoodRx Holdings, Inc.GDRX | 39.1/100Mixed-negative evidence65% evidence | BREAKING OUT | 8.2/35 Revenue -1.3% · PAT -31% · OPM change -4.3 pp 83% evidence | 11.0/25 ROCE 1.2% · OPM 7.2% 76% evidence | 10.4/20 P/E 32.7× · PEG — 15% evidence | 9.5/20 RS sector -7.7% · RS bench 10.1% · 1Y -17.9%12 of 12 weeks ahead 70% evidence |
| Exact sum: 8.2 + 11 + 10.4 + 9.5 = 39.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Talkspace, Inc.TALK | 37.3/100Mixed-negative evidence64% evidence | 12.8/35 Revenue 22.7% · PAT -66.7% · OPM change -9.5 pp 62% evidence | 6.0/25 ROCE -6.2% · OPM -11.6% 76% evidence | 8.5/20 P/E 517.5× · PEG — 15% evidence | 10.0/20 RS sector -2.5% · RS bench 12.4% · 1Y 105.1%0 of 7 weeks ahead to 2026-08-14 100% evidence | |
| Exact sum: 12.8 + 6 + 8.5 + 10 = 37.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Claritev CorporationCTEV | 37.3/100Thin evidence · provisional55% evidence | BREAKING OUT | 12.8/35 Revenue 5.8% · PAT — · OPM change -3.1 pp 62% evidence | 8.9/25 ROCE 0.1% · OPM 2.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.6/20 RS sector -19.7% · RS bench -5.4% · 1Y -35.1%10 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 8.9 + 10 + 5.6 = 37.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Certara, Inc.CERT | 35.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 11.8/35 Revenue 6.8% · PAT — · OPM change -11.2 pp 62% evidence | 8.8/25 ROCE -0.3% · OPM -4% 76% evidence | 8.7/20 P/E 174.6× · PEG — 15% evidence | 6.2/20 RS sector -19.4% · RS bench -3.8% · 1Y -29.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 11.8 + 8.8 + 8.7 + 6.2 = 35.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Spok Holdings, Inc.SPOK | 34.4/100Adverse evidence75% evidence | TURNING | 7.9/35 Revenue -1.4% · PAT -18.8% · OPM change -9.2 pp 83% evidence | 13.0/25 ROCE 1.6% · OPM 7.4% 76% evidence | 9.4/20 P/E 18.2× · PEG 2.25 65% evidence | 4.1/20 RS sector -33.1% · RS bench -18.9% · 1Y -38.7%0 of 12 weeks ahead 70% evidence |
| Exact sum: 7.9 + 13 + 9.4 + 4.1 = 34.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Evolent Health, Inc.EVH | 33.5/100Thin evidence · provisional55% evidence | ASLEEP | 11.0/35 Revenue -21.3% · PAT — · OPM change -1.8 pp 62% evidence | 8.1/25 ROCE -0.6% · OPM -2.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.4/20 RS sector -32.4% · RS bench -19.8% · 1Y -55.4%7 of 12 weeks ahead 70% evidence |
| Exact sum: 11 + 8.1 + 10 + 4.4 = 33.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28American Well CorporationAMWL | 51.1/100Thin evidence · provisional44% evidence | LEADER | 19.7/35 Revenue — · PAT — · OPM change 13.8 pp 32% evidence | 4.7/25 ROCE -6.3% · OPM -31.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.7/20 RS sector 47.1% · RS bench 75.4% · 1Y 107.6%12 of 12 weeks ahead 70% evidence |
| Exact sum: 19.7 + 4.7 + 10 + 16.7 = 51.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Teladoc Health, Inc.TDOC | 40.1/100Thin evidence · provisional49% evidence | ASLEEP | 18.3/35 Revenue — · PAT — · OPM change 9.1 pp 45% evidence | 6.9/25 ROCE -1.9% · OPM -10.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.9/20 RS sector -27.4% · RS bench -12.9% · 1Y -19.1%4 of 12 weeks ahead 70% evidence |
| Exact sum: 18.3 + 6.9 + 10 + 4.9 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Doximity, Inc.'s stock price today?
Doximity, Inc. trades at $25.9, −64.4% over the past year. The company is valued at $5.0 B. The stock sits at 13% of its 52-week range of $19–$74, −7.5% versus its 200-day average. On the tape, the price is in a downtrend, 31 weeks in. — as of 17 September 2026.
What were Doximity, Inc.'s latest quarterly results?
Doximity, Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 7.1% and profit fell 66.7% year on year. Earnings per share were $0.10. The operating margin was 13.3%, 22.4 pp lower than a year earlier. — as of 17 September 2026.
What is Doximity, Inc.'s revenue?
Doximity, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +7.1% year on year. For the full FY26 fiscal year, revenue was $0.6 B (+12.3%). Over the last 4 years revenue compounded at 17.1% a year. — as of 17 September 2026.
What is Doximity, Inc.'s profit?
Doximity, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −66.7% year on year. Full-year FY26 profit was $0.2 B. The operating margin ran 13.3% in the latest quarter. — as of 17 September 2026.
What is Doximity, Inc.'s market cap?
Doximity, Inc.'s market capitalisation is $5.0 B at a stock price of $25.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does Doximity, Inc. pay a dividend?
No — Doximity, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Doximity, Inc. growing?
Not right now — Doximity, Inc.'s latest numbers are shrinking: latest-quarter revenue +7.1% year on year, profit −66.7%, and the margin −22.4 pp at 13.3%. The 4-year compound rates are 17.1% (revenue) and 7.5% (profit). The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Doximity, Inc. performing?
Doximity, Inc. is in a downtrend, 31 weeks in. Its latest quarter's revenue rose 7.1% and profit fell 66.7% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Doximity, Inc. in?
Topping out — profit and EPS growth have decelerated hard (profit growth +46.7% at its peak → −13.6% latest) while ROCE still reads 19.3%. The read comes from the last 12 quarters of growth (revenue growth +13.8% latest, profit growth −13.6% latest, eps growth −10.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Doximity, Inc. in an uptrend?
No — the price is in a downtrend (week 31 of stage 4), trading −7.5% versus its 200-day average and at 13% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Doximity, Inc. beating the market?
On recent form, yes — Doximity, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 7 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.2 years the stock moved −54% against the S&P 500's +77% — behind the index over the full window. — as of 17 September 2026.
Will Doximity, Inc.'s stock price go up?
This page publishes no price forecast for Doximity, Inc. What it measures instead: the stock price is $25.9, the price is in a downtrend 31 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Doximity, Inc.?
Yes — short interest is 11.4% of Doximity, Inc.'s tradable float, about 1.9 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Doximity, Inc. have too much debt?
No — Doximity, Inc.'s debt-to-equity is 0.01. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is Doximity, Inc.'s capex?
Doximity, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY24 alone that was $0.0 B. — as of 17 September 2026.
What is Doximity, Inc.'s cash flow?
Doximity, Inc. generated $0.3 B of operating cash flow in FY26 and $0.3 B of free cash flow after null of capital spending. Reported profit that year was $0.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Doximity, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 137% of Doximity, Inc.'s reported profit arrived as operating cash. In FY26, operating cash was $0.3 B against reported profit of $0.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Doximity, Inc.?
On the balance sheet, the Z-score reads 31.30 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Doximity, Inc. in its business cycle?
Doximity, Inc.'s FY26 operating margin was 32.8%, against a 5-year band of 31.0%–40.4%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 13.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Doximity, Inc. story?
The sharpest disagreement: annual EPS moved −11.7% against a −64.4% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Doximity, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Doximity, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!